atai Life Sciences (ATAI)
(Real Time Quote from BATS)
$1.54 USD
+0.03 (1.99%)
Updated Jul 25, 2024 09:58 AM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATAI 1.54 +0.03(1.99%)
Will ATAI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATAI
atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice
ATAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
Other News for ATAI
Here's What You Missed in Cannabis, Psychedelics This Week
Here's What You Missed in Cannabis, Psychedelics This Week
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
Largest Clinical-Stage Biotech Drug Stocks Declined 6%
Largest Clinical-Stage BioTech Drug Stocks Declined 6%